| 1. |
- Funehag, Johan, et al.
(author)
-
Rock Excavation Cycle and Its Effect on Grouting
- 2019
-
In: ISRM 9th Nordic Grouting Symposium. - : International Society for Rock Mechanics and Rock Engineering. - 9789517586481 ; , s. 47-59
-
Conference paper (other academic/artistic)abstract
- The drill and blast rock excavation cycle involves several processes that affects the grouting; vibration from drilling, borehole flushing, the blasting itself and water-loss measurements in boreholes. This research project focused on the effects of water-loss measurements, drilling (both vibration and flushing) and blasting on the grout and during the first five hours of the hardening process. A conceptual model was derived to explain what forces acts on the grout and how the forces can be interpreted in order to reveal how these forces effects the grout. The model suggests that the shear modulus of the grout is a key parameter for understanding the degradation of the grout. The different forces/stresses during an excavation effects the grout differently but the blasting is by far the most difficult process to describe. One starting point of the project is that the grout does not reinforce the rock and by that should not hinder the gas expansion. The blasting should generate new fractures around the blast hole and the gas will penetrate these cracks and finally the expansion of gases should cause fragmentation and movement in the rock mass. The paper describes the results from the field test and how the grout has been characterized using a rheometer. The field test was conducted in a short tunnel niche. The effects from the drill- and blast cycle were studied i.e. vibrations from drilling, boreholes flushing/water-loss measurements and vibrations from blasting. Five boreholes with a centrum distance of 1 m were chosen to be monitored, due to its hydraulic connectivity between the boreholes. Four of these boreholes were successfully grouted by following a grouting design and one borehole was left un-grouted and used for blasting. The effect on grouting in the rock mass from hole of blasting was measured using water-loss measurements in adjacent boreholes. One result of the field test is that the grout was not affected by the blasting under the circumstances used. Instead the study revealed that the water loss measurements affected the connected boreholes negatively.
|
|
| 2. |
- Jansson Löfmark, Rasmus, 1979, et al.
(author)
-
Enantiospecific Reassessment of the Pharmacokinetics and Pharmacodynamics of Oral Eflornithine against Late-Stage Trypanosoma brucei gambiense Sleeping Sickness
- 2015
-
In: Antimicrobial Agents and Chemotherapy. - : American Society for Microbiology. - 0066-4804 .- 1098-6596. ; 59:2, s. 1299-1307
-
Journal article (peer-reviewed)abstract
- This study aimed to characterize the stereoselective pharmacokinetics of oral eflornithine in 25 patients with late-stage Trypanosoma brucei gambiense sleeping sickness. A secondary aim was to determine the concentrations of L-and D-eflornithine required in plasma or cerebrospinal fluid (CSF) for an efficient eradication of the T. brucei gambiense parasites. Patients were randomly allocated to receive either 100 (group I, n = 12) or 125 (group II, n = 13) mg/kg of body weight of drug every 6 h for 14 days. The concentrations of L-and D-eflornithine in the plasma and CSF samples were measured using a stereospecific liquid chromatographic method. Nonlinear mixed-effects modeling was used to characterize the plasma pharmacokinetics. The plasma concentrations of L-eflornithine were on average 52% (95% confidence interval [CI], 51, 54%; n = 321) of the D-enantiomer concentrations. The typical oral clearances of L-and D-eflornithine were 17.4 (95% CI, 15.5, 19.3) and 8.23 (95% CI, 7.36, 9.10) liters/h, respectively. These differences were likely due to stereoselective intestinal absorption. The distributions of eflornithine enantiomers to the CSF were not stereoselective. A correlation was found between the probability of cure and plasma drug exposure, although it was not more pronounced for the L-enantiomer than for that of total eflornithine. This study may explain why oral treatment for late-stage human African trypanosomiasis (HAT) patients with racemic eflornithine has previously failed; the more potent L-enantiomer is present at much lower concentrations in both plasma and CSF than those of the D-enantiomer. Eflornithine stereoselective pharmacokinetics needs to be considered if an oral dosage regimen is to be explored further.
|
|
| 3. |
- Pålhagen, Sven E., et al.
(author)
-
Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinsons disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs
- 2016
-
In: Parkinsonism & Related Disorders. - : ELSEVIER SCI LTD. - 1353-8020 .- 1873-5126. ; 29, s. 17-23
-
Journal article (peer-reviewed)abstract
- Background: Continuous infusion of levodopa-carbidopa intestinal gel (LCIG) can effectively manage motor and non-motor complications in advanced Parkinsons disease (PD). Healthcare costs, quality of life (QoL), effectiveness, and tolerability were assessed in routine care treatment with LCIG. Methods: The seventy-seven patients enrolled in this prospective, open-label, 3-year study in routine medical care were LCIG-naive (N = 37), or had previous LCIG treatment for amp;lt;2 (N = 22), or amp;gt;= 2 (N = 18) years. Healthcare costs were collected monthly. PD symptoms and QoL were assessed with the Unified Parkinsons Disease Rating Scale (UPDRS), 39-item Parkinsons Disease Questionnaire (PDQ-39), and EuroQoL 5-Dimension Visual Analog Scale (EQ-5D VAS); LCIG dose, safety, and tolerability were monitored. Results: Mean monthly costs per patient ( 8226 5952) were similar across cohorts, remained steady during 3-year follow-up, and increased with PD severity and QoL impairment. In LCIG-naive patients, significant improvements compared to baseline were observed on the UPDRS total score and PDQ-39 summary index score through 18 months (n = 24; UPDRS, p = 0.033; PDQ-39, p = 0.049). Symptom control was maintained during 3-year follow-up in LCIG-experienced cohorts. Small changes in mean daily LCIG dose were observed. Adverse events were common and generally related to the device, procedure, levodopa, or laboratory evaluations. Conclusions: Costs in LCIG-treated patients were stable over 3 years. LCIG treatment led to significant improvements in motor function and QoL over 18 months in LCIG-naive patients and no worsening was observed in LCIG-experienced patients over 3 years despite natural PD progression over time. The longterm safety was consistent with the established LCIG profile. (C) 2016 AbbVie Inc. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
|
|
